Discordance between serum cholesterol concentration and atherogenic lipoprotein particle number in people with metabolic disease: A systematic review
Authors' conclusion
While LDL-C remains a central marker for ASCVD, apoB quantification provides a more accurate assessment of ASCVD risk, particularly in individuals with metabolic diseases.
Study context
- Population
- Individuals with metabolic disease (metabolic syndrome, T2D); fasted blood samples; studies of drug therapies or dietary interventions excluded9 studies
- Comparison
- Low-density lipoprotein cholesterol (LDL-C) vs non-HDL-C vs apoB
- Outcome
- Discordance between LDL-C, non-HDL-C and apoB and implications for ASCVD risk assessment
Methodological detailsobservational studies, Search of Academic Search Complete, CINAHL Complete and MEDLINE, 10 January 2024 to 28 May 2024
- Observational studies
- Search of Academic Search Complete, CINAHL Complete and MEDLINE, 10 January 2024 to 28 May 2024
Pooled result
As reported in the abstract
Discordance between LDL-C and apoB
- Significant discordance between LDL-C and apoB levels in metabolic syndrome or T2D
- Optimal LDL-C levels often achieved while apoB and non-HDL-C concentrations are elevated
Further pooled results
Mechanisms of discordance
- Discordance largely attributed to differences in LDL particle size and density; metabolic disease contributes a higher proportion of small, dense, atherogenic LDL particles
- Elevated triglyceride-rich lipoproteins (TRLs) (e.g. Very low-density lipoproteins (VLDL)) contribute to atherosclerotic cardiovascular disease (ASCVD) risk underestimation by LDL-C
Original publication
Discordance between serum cholesterol concentration and atherogenic lipoprotein particle number in people with metabolic disease: A systematic review. Diabetes Obes Metab. Published 16 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →